Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
ABBV
Home
/
ABBV

NYSE
$288.92
$288.92

Overview

Price performance
Low
$283.32
High
$293.95
Market open. Last updated: Nov 4, 2026, 4:34 PM UTC
$
288.92
2.92 (1.02%)
Average, 50 days
$270.20
$237.81
Open
$293.95
Previous close
$286.00
52-week high
$298.74
Oct 30, 2026 (6 days ago)
52-week low
$190.75
Apr 29, 2026 (7 months ago)
51.47%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
510.56B
Volume
2 583 471
Total Return (3M)
18.51%
Total Return (1Y)
33.83%
13.65
Sector
Healthcare
Links
Tags
Healthcare
Drug Manufacturers - General
NYSE
US
Website
abbvie.com
Socials
About
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Frequently asked questions

ABBV · AbbVie Inc.

01What is AbbVie Inc. stock price today?

The current price of ABBV is $288.92 — it has increased by 1.02% since the previous close. Data as of Nov 4, 2026.

02Is AbbVie Inc. stock price growing?

ABBV is down 1.05% over the past week, up 9.93% over the past month and up 33.83% over the past year. The price is above its 200-day moving average of $237.81.

03What is ABBV stock forecast?

Analysts' average 12-month price target for ABBV is $307.94, which implies 6.58% upside from the current price. Individual estimates range from $235.00 to $340.00.

04What do analysts say about ABBV stock?

Of the 29 analysts covering AbbVie Inc., 7 rate it a strong buy, 16 rate it a buy, 5 rate it a hold and 1 rates it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is AbbVie Inc. market cap?

AbbVie Inc. has a market capitalization of $510.56B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were AbbVie Inc. earnings last quarter?

In its most recent quarterly report, AbbVie Inc. posted earnings of $3.82 per share against an estimate of $3.73, beating expectations by 2.41%. Upcoming reports are listed in the earnings calendar.

07What is AbbVie Inc. revenue for the last quarter?

AbbVie Inc. reported revenue of $17.4B in its most recent quarter, which has increased by 10.32% compared with the same quarter a year earlier. Analysts had expected $17.32B.

08Who are AbbVie Inc. competitors?

Companies most comparable to AbbVie Inc. include Eli Lilly and Company, Johnson & Johnson, Roche Holding AG, Merck & Co., Inc. and Novartis AG.

09How volatile is ABBV stock?

In the latest trading session ABBV moved between $283.32 and $293.95, a range of 3.68% of its current price.

10What are ABBV stock 52-week high and low?

Over the past 52 weeks ABBV has traded between $190.75 and $298.74. The current price is 3.29% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.